Literature DB >> 11243870

A single nucleotide polymorphism of CYP2b6 found in Japanese enhances catalytic activity by autoactivation.

N Ariyoshi1, M Miyazaki, K Toide, T Kamataki.   

Abstract

A single nucleotide polymorphism (SNP) resulting in a substitution from Gln to His was found in exon 4 of the CYP2B6 gene in Japanese. The frequency of the variant allele was found to be 19.9%. The mutant- and the wild-type enzymes were expressed in Escherichia coli, and the effects of the single amino acid substitution on the catalytic activity were examined by investigating the kinetic profiles of 7-ethoxycoumarin O-deethylase activity. The wild-type enzyme showed typical Michaelis-Menten kinetics, while the mutant-type enzyme represented the sigmoidal kinetics with a higher V(max) value compared to that of the wild-type enzyme. Eadie-Hofstee plots further revealed an existence of allosteric effects for the reaction catalyzed by the variant. This is the first evidence demonstrating that only one amino acid substitution, Gln172His, caused by natural SNP enhances the catalytic activity of CYP by obtaining the character of homotropic cooperativity. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11243870     DOI: 10.1006/bbrc.2001.4524

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  34 in total

Review 1.  Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism.

Authors:  Maarten J Deenen; Annemieke Cats; Jos H Beijnen; Jan H M Schellens
Journal:  Oncologist       Date:  2011-05-31

2.  High-throughput screening assays for CYP2B6 metabolism and inhibition using fluorogenic vivid substrates.

Authors:  Bryan D Marks; Tony A Goossens; Heidi A Braun; Mary S Ozers; Ronald W Smith; Connie Lebakken; Olga V Trubetskoy
Journal:  AAPS PharmSci       Date:  2003

3.  Anandamide oxidation by wild-type and polymorphically expressed CYP2B6 and CYP2D6.

Authors:  Chitra Sridar; Natasha T Snider; Paul F Hollenberg
Journal:  Drug Metab Dispos       Date:  2011-02-02       Impact factor: 3.922

4.  Frequencies of Cytochrome P450 2B6 and 2C8 Allelic Variants in the Mozambican Population.

Authors:  Paulo Arnaldo; Ricardo Estevão Thompson; Márcia Quinhones Lopes; Philip Noel Suffys; Adalberto Rezende Santos
Journal:  Malays J Med Sci       Date:  2013-07

5.  Role of subunit interactions in P450 oligomers in the loss of homotropic cooperativity in the cytochrome P450 3A4 mutant L211F/D214E/F304W.

Authors:  Harshica Fernando; Dmitri R Davydov; Christopher C Chin; James R Halpert
Journal:  Arch Biochem Biophys       Date:  2007-01-12       Impact factor: 4.013

6.  Mechanism of interactions of alpha-naphthoflavone with cytochrome P450 3A4 explored with an engineered enzyme bearing a fluorescent probe.

Authors:  Tamara N Tsalkova; Nadezhda Y Davydova; James R Halpert; Dmitri R Davydov
Journal:  Biochemistry       Date:  2007-01-09       Impact factor: 3.162

7.  Prevalence of CYP2B6 alleles in malaria-endemic populations of West Africa and Papua New Guinea.

Authors:  Rajeev K Mehlotra; Mark N Ziats; Moses J Bockarie; Peter A Zimmerman
Journal:  Eur J Clin Pharmacol       Date:  2006-02-28       Impact factor: 2.953

Review 8.  Efavirenz Metabolism: Influence of Polymorphic CYP2B6 Variants and Stereochemistry.

Authors:  Pan-Fen Wang; Alicia Neiner; Evan D Kharasch
Journal:  Drug Metab Dispos       Date:  2019-07-19       Impact factor: 3.922

9.  Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa.

Authors:  Corine Ekhart; Valerie D Doodeman; Sjoerd Rodenhuis; Paul H M Smits; Jos H Beijnen; Alwin D R Huitema
Journal:  Br J Clin Pharmacol       Date:  2008-11-17       Impact factor: 4.335

10.  Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide.

Authors:  J Bray; J Sludden; M J Griffin; M Cole; M Verrill; D Jamieson; A V Boddy
Journal:  Br J Cancer       Date:  2010-02-23       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.